KY003

KY003 (also known as KY1103) is an investigational therapeutic candidate being developed by KYDES Pharmaceuticals. It is designed as a locally intensive therapy for the treatment of various benign and malignant gynecological disorders. The development program for KY003 targets a broad range of indications, including cervical, vaginal, and uterine cancers, as well as benign conditions such as heavy menstrual bleeding, adenomyosis, endometriosis, cervical dysplasia, and uterine fibroids. While the specific molecular mechanism of action and modality have not been publicly disclosed, the locally intensive approach suggests a focus on achieving high local drug concentrations to maximize efficacy while minimizing systemic exposure in the female reproductive tract.

Other names

KY1103KY-1103KY 1103